<DOC>
	<DOCNO>NCT01738191</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness drug call atomoxetine treatment cognitive impairment Parkinson 's disease . Atomoxetine ( ATM ) approve drug currently market treatment attention deficit . It work increase amount norepinephrine ( chemical brain help keep u awake alert ) brain . ATM approve Food Drug Administration ( FDA ) use treatment PD .</brief_summary>
	<brief_title>Atomoxetine Treatment Cognitive Impairment Parkinson 's Disease ( ATM-Cog )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Confirmed diagnosis idiopathic PD accord United Kingdom Parkinson 's Disease Society Brain Bank ( UKPDSBB ) criteria Male female subject age 35 75 year , inclusive time consent Hoehn &amp; Yahr Stage IIV Diagnosis PD mild cognitive impairment ( MCI ) , Montreal Cognitive Assessment ( MoCa ) score 2125 Stable concomitant medication 60 day Secondary parkinsonism atypical parkinsonism , Prior Deep Brain Stimulation ( DBS ) brain surgery PD Dementia ; MoCA score &lt; 21 Presence Psychosis , pregnancy , suicidal ideation Columbia Suicide Severity Rating Scale ( CSSRS ) type 4 5 past 3 month . Current treatment anticholinergic , monoamine oxidase ( MAO ) inhibitor neuroleptic ( include quetiapine ) Serious cardiac abnormality , Narrow angle glaucoma , Pheochromocytoma , Bipolar Disorder Liver Function Tests ( LFTs ) &gt; 1.5 X upper limit normal value</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
</DOC>